PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report

Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasent Blesa, Joan Manel, Godoy, Miguel Peris, Esparcia, María Fonfría, Mollá, Sara Blasco, Magán, Balbino Mancheño, Sempere Ortells, José Miguel, Sánchez, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: April, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364036/
https://www.ncbi.nlm.nih.gov/pubmed/22666210
http://dx.doi.org/10.1159/000336481
Descripción
Sumario:Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence supports the role of the immunomodulatory agent lenalidomide in HRPC. In this paper, we report that lenalidomide showed antitumoral activity in a patient with HRPC and bone metastases pre-treated with chemotherapy, decreased the PSA level and improved the patient's health status for the first 5 months. It is important to emphasize that it was not associated with hematologic toxicity.

Ejemplares similares